East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Allopurinol Tablets USP, 100 mg and 300 mg. Aurobindo Pharma’s Allopurinol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Zyloprim Tablets manufactured by Casper Pharma LLC.

Allopurinol Tablets are indicated in the management of:

• Patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy)
• Patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels
• Patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients.